Interleukin-18 as a target for modulation of irinotecan-induced intestinal toxicity: a step towards a better therapeutic index?: Commentary on Lima-Junior et al., Br J Pharmacol 171: 2335-2350.
First Department of Propaedeutic Surgery, School of Medicine, University of Athens, Athens, Greece.
B G
BG
Spyropoulos
D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives*; D016503:Drug Delivery Systems / Q000379:methods*; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage*; D020382:Interleukin-18 / Q000037:antagonists & inhibitors*; D007413:Intestinal Mucosa / Q000187:drug effects*; D052016:Mucositis / Q000188:drug therapy*
D036341:Intercellular Signaling Peptides and Proteins; D020382:Interleukin-18; D002166:Camptothecin
chemotherapy-induced mucosal injury; diarrhoea; interleukin-18; irinotecan; mucositis